Invitrogen™ CD262 (DR5) Monoclonal Antibody (DJR2-4 (7-8)), eBioscience™, Invitrogen™

Catalog No.	Quantity
14-990-837	2 mg
14-990-895	10 mg

Catalog No. 14-990-837 Supplier Invitrogen™ Supplier No. 14990837

Description

Mouse Monoclonal Antibody

Description: The DJR2-4 monoclonal antibody reacts with human DR5, also known as TRAIL-R2, Apo2, TRICK2 and KILLER. DR5 binds to TRAIL, activates NF-kappaB, and induces TRAIL-mediated apoptosis. DR5 is expressed broadly by normal tissues as well as several tumor cells. Applications Reported: The DJR2-4 (a.k.a. 7-8) antibody has been reported for use in flow cytometric analysis. Applications Tested: The DJR2-4 (a.k.a. 7-8) antibody has been tested by flow cytometric analysis of human MOLT-4 cell line and human DR5-transfected cells. This can be used at less than or equal to 1 μg per test. A test is defined as the amount (μg) of antibody that will stain a cell sample in a final volume of 100 μL. Cell number should be determined empirically but can range from 10^5 to 10^8 cells/test. It is recommended that the antibody be carefully titrated for optimal performance in the assay of interest. Purity: Greater than 90%, as determined by SDS-PAGE. Aggregation: Less than 10%, as determined by HPLC. Filtration: 0.2 μm post-manufacturing filtered.

DR5 (Apo2, TRAIL-R2, TRICK2, KILLER) is a recently identified death domain containing receptor for TRAIL, which mediates TRAIL induced apoptosis. DR5 is a member of the TNF-receptor superfamily, and contains an intracellular death domain. DR5 can be activated by tumor necrosis factor-related apoptosis inducing ligand (TNFSF10/TRAIL/APO-2L), and transduces an apoptosis signal. Studies with FADD-deficient mice suggested that FADD, a death domain containing adaptor protein, is required for the apoptosis mediated by DR5. Two transcript variants encoding different isoforms of DR5 and one non-coding transcript have been found. Overexpression of DR5 induces apoptosis and activates NF-kappa-B. DR5 is expressed in a number of cell types, and to particularly high levels in lymphocytes and spleen. Diseases associated with DR5 dysfunction include squamous cell carcinoma, and diffuse infiltrative lymphocytosis syndrome.

Specifications

• Antigen: CD262 (DR5)
• Applications: Flow Cytometry, Immunocytochemistry
• Classification: Monoclonal
• Clone: DJR2-4 (7-8)
• Concentration: 0.5 mg/mL
• Conjugate: Unconjugated
• Formulation: PBS with 0.09% sodium azide; pH 7.2
• Gene: TNFRSF10B
• Gene Accession No.: O14763
• Gene Alias: apoptosis inducing protein TRICK2A/2B; apoptosis inducing receptor TRAIL-R2; CD262; cytotoxic TRAIL receptor-2; death domain containing receptor for TRAIL/Apo-2L; death receptor 5; Dr5; dr-5; Fas-like protein; KILLER; KILLER/DR5; KILLER/DR5 TRAIL death-inducing receptor; Ly98; MK; p53-regulated DNA damage-inducible cell death receptor(killer); sCD262; soluble CD262; TNF receptor superfamily member 10b; TNF-related apoptosis-inducing ligand receptor 2; TNFRSF10B; TRAIL receptor 2; TRAILR2; TRAIL-R2; TRICK2; TRICK2A; TRICK2B; TRICKB; tumor necrosis factor receptor superfamily member 10B; tumor necrosis factor receptor superfamily, member 10b; tumor necrosis factor receptor-like protein ZTNFR9; UNQ160/PRO186; ZTNFR9
• Gene Symbols: TNFRSF10B
• Host Species: Mouse
• Purification Method: Affinity chromatography
• Quantity: 2 mg
• Regulatory Status: RUO
• Primary or Secondary: Primary
• Gene ID (Entrez): 8795
• Target Species: Human
• Content And Storage: 4°C
• Product Type: Antibody
• Form: Liquid
• Isotype: IgG1 κ

Safety and Handling

WARNING: Cancer - www.P65Warnings.ca.gov